Based on our in vivo data, iNOS antagonism represents a promising approach to tackling aortic aneurysms related to SMAD3 mutations, and it merits further investigation as an adjunctive strategy for AOS patients to prevent major life‐threatening manifestations of this disorder. The gene discussed is SMAD3; the disease is aortic aneurysm.